Allos Therapeutics, Inc. to Launch Global Registry for Patients with Peripheral T-Cell Lymphoma at the American Society of Hematology Annual Meeting

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the launch of an international registry designed to address the urgent need to better understand treatment patterns and outcomes for patients with peripheral T-cell lymphoma (PTCL). The registry, known as COMPLETE (Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment), is a global observational study that will enroll patients with newly-diagnosed PTCL and obtain data regarding longitudinal treatment patterns and outcomes. Complementing other registries that focus on PTCL incidence or prognosis at diagnosis, COMPLETE is expected to provide – for the first time – important and detailed information on PTCL disease management across various treatment regimens, including drug therapy, stem cell transplant and radiation therapy. The registry will be launched during the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA.